In Vivo Scientist / Senior Scientist

South San Francisco, California
Oct 19, 2020
Biotech Bay
Required Education
Masters Degree/MBA
Position Type
Full time

In Vivo Scientist / Senior Scientist

Primary Duties and Responsibilities:  This is an exciting opportunity to join the Apollomics Discovery group. We are dedicated to discovering innovative immunotherapeutic modalities. The successful candidate will become a key individual contributor to advance research stage programs into early clinical development. This position is ideal for talented, highly motivated, and data-oriented individuals with a strong desire to work for a startup company. 

  • Conduct implantation, dosing (IV, IP, PO, SC, IM, IT), blood sampling, tumor measurement, tissue harvest, and data recording.
  • Enter, record data in multiple databases
  • Independently plan and execute in vivo studies using good documentation practice and strict adherence to all guidelines and policies
  • Monitor animal health and assist with the treatment of animals
  • Provide other forms of study support, such as ear tagging, randomizing, coordination of activities, and breeding of transgenic strains
  • Writing/maintaining IACUC protocols and ensuring that all experimental methods and results are saved in Electronic Laboratory Notebook in a timely fashion


  • The level of the position will depend on the qualifications of the selected candidate.
  • BS or MS degree in biology or related science 
  • Industry (Pharma/Biotech/CRO) hands-on experiences required for in vivo techniques and murine model development
  • Proficiency in SC and orthotopic implantation; IP, IV, SC, and PO dosing, blood, and tissue collection
  • Experience with oncology or immunology projects preferred
  • Willingness to work a flexible schedule (off core hours, weekends, and holidays) as necessary
  • Preferred experience managing successful collaborations with CROs and vendor partners

Apollomics, Inc. is an innovative biopharmaceutical company committed to the discovery and development of oncology combination therapies that harness the immune system and target specific molecular pathways to eradicate cancer globally. The company’s existing pipeline consists of five development-stage assets including two novel humanized monoclonal antibodies that restore the body’s immune system to recognize and kill cancer cells, and three targeted therapies against uncontrolled growth signaling pathways.